MedTrace Logo

ENERGI-F703 for Diabetic Foot Ulcers Phase II Study

NCT02672436 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2020-11-24

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of ENERGI-F703 in subject with diabetic foot ulcers.

Conditions

Interventions

DRUG

ENERGI-F703

Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.

DRUG

ENERGI-F703 matched vehicle

Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.

Sponsors & Collaborators

  • A2 Healthcare Taiwan Corporation

    collaborator INDUSTRY

  • Energenesis Biomedical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2019-10-03
Completion
2019-12-26
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672436 on ClinicalTrials.gov